Selegiline in the treatment of sexual dysfunction in schizophrenic patients maintained on neuroleptics: A pilot study

Arad Kodesh; Abraham Weizman; Dov Aizenberg; Haggai Hermesh; Marc Gelkopf; Zvi Zemishlany

doi:10.1097/00002826-200307000-00008

Selegiline in the treatment of sexual dysfunction in schizophrenic patients maintained on neuroleptics: A pilot study

Arad Kodesh, Abraham Weizman, Dov Aizenberg, Haggai Hermesh, Marc Gelkopf, Zvi Zemishlany

Research output: Contribution to journal › Article › peer-review

Abstract

A double-blind, placebo-controlled crossover study was undertaken in 10 neuroleptic-treated male schizophrenic outpatients to assess the effect of coadministration of selegiline 15 mg/day for 3 weeks on their sexual dysfunction. Selegiline was not found to be effective in improving any domain of sexual functioning despite a significant decrease in prolactin levels (P < 0.05). This study emphasizes the complex nature of sexual dysfunction in schizophrenic-treated patients and the need for placebo-controlled trials for this condition.

Original language	English
Pages (from-to)	193-195
Number of pages	3
Journal	Clinical Neuropharmacology
Volume	26
Issue number	4
DOIs	https://doi.org/10.1097/00002826-200307000-00008
State	Published - Jul 2003
Externally published	Yes

Keywords

Antipsychotics
Dopamine
L-deprenyl
Neuroleptics
Schizophrenia
Selegiline
Sexual dysfunction

ASJC Scopus subject areas

Pharmacology
Clinical Neurology
Pharmacology (medical)

Access to Document

10.1097/00002826-200307000-00008

Cite this

@article{8fa2c4d3b0514c6fbb5dceb56ce8592c,

title = "Selegiline in the treatment of sexual dysfunction in schizophrenic patients maintained on neuroleptics: A pilot study",

abstract = "A double-blind, placebo-controlled crossover study was undertaken in 10 neuroleptic-treated male schizophrenic outpatients to assess the effect of coadministration of selegiline 15 mg/day for 3 weeks on their sexual dysfunction. Selegiline was not found to be effective in improving any domain of sexual functioning despite a significant decrease in prolactin levels (P < 0.05). This study emphasizes the complex nature of sexual dysfunction in schizophrenic-treated patients and the need for placebo-controlled trials for this condition.",

keywords = "Antipsychotics, Dopamine, L-deprenyl, Neuroleptics, Schizophrenia, Selegiline, Sexual dysfunction",

author = "Arad Kodesh and Abraham Weizman and Dov Aizenberg and Haggai Hermesh and Marc Gelkopf and Zvi Zemishlany",

year = "2003",

month = jul,

doi = "10.1097/00002826-200307000-00008",

language = "English",

volume = "26",

pages = "193--195",

journal = "Clinical Neuropharmacology",

issn = "0362-5664",

publisher = "Lippincott Williams and Wilkins Ltd.",

number = "4",

}

TY - JOUR

T1 - Selegiline in the treatment of sexual dysfunction in schizophrenic patients maintained on neuroleptics

T2 - A pilot study

AU - Kodesh, Arad

AU - Weizman, Abraham

AU - Aizenberg, Dov

AU - Hermesh, Haggai

AU - Gelkopf, Marc

AU - Zemishlany, Zvi

PY - 2003/7

Y1 - 2003/7

N2 - A double-blind, placebo-controlled crossover study was undertaken in 10 neuroleptic-treated male schizophrenic outpatients to assess the effect of coadministration of selegiline 15 mg/day for 3 weeks on their sexual dysfunction. Selegiline was not found to be effective in improving any domain of sexual functioning despite a significant decrease in prolactin levels (P < 0.05). This study emphasizes the complex nature of sexual dysfunction in schizophrenic-treated patients and the need for placebo-controlled trials for this condition.

AB - A double-blind, placebo-controlled crossover study was undertaken in 10 neuroleptic-treated male schizophrenic outpatients to assess the effect of coadministration of selegiline 15 mg/day for 3 weeks on their sexual dysfunction. Selegiline was not found to be effective in improving any domain of sexual functioning despite a significant decrease in prolactin levels (P < 0.05). This study emphasizes the complex nature of sexual dysfunction in schizophrenic-treated patients and the need for placebo-controlled trials for this condition.

KW - Antipsychotics

KW - Dopamine

KW - L-deprenyl

KW - Neuroleptics

KW - Schizophrenia

KW - Selegiline

KW - Sexual dysfunction

UR - http://www.scopus.com/inward/record.url?scp=0041633786&partnerID=8YFLogxK

U2 - 10.1097/00002826-200307000-00008

DO - 10.1097/00002826-200307000-00008

M3 - Article

C2 - 12897639

AN - SCOPUS:0041633786

SN - 0362-5664

VL - 26

SP - 193

EP - 195

JO - Clinical Neuropharmacology

JF - Clinical Neuropharmacology

IS - 4

ER -

Selegiline in the treatment of sexual dysfunction in schizophrenic patients maintained on neuroleptics: A pilot study

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this